In vivo neutralization of Vascular Endothelial Growth Factor (VEGF)/Vascular Permeability Factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth

Timothy A. Olson, D. Mohanraj, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) is emerging as an important growth factor in a variety of tumor types. As a potent endothelial cell mitogen and vascular permeabilizing agent, VEGF/VPF has the unique functional capacity to mediate the component events of solid tumor neovascularization and ascites tumor growth. In the present series of investigations, our experimental hypothesis was that VEGF/VPF is a critical mediator of ovarian carcinoma-associated ascites formation and solid tumor growth. Athymic nude mice xenotransplanted with human ovarian carcinoma cell lines received either a preimmune rabbit serum or VEGF/VPF antiserum. Compared with the control group receiving the preimmune serum, the antiserum-treated animals displayed a 10- and 12-fold reduction in ascites accumulation and solid tumor growth, respectively. The administration of a neutralizing antiserum to VEGF/VPF conferred a modest survival advantage to animals harboring intraperitoneal tumors. These data demonstrate the significance of VEGF/VPF in the pathogenesis of ovarian carcinoma and suggest that interventions targeting this growth factor and/or its receptor may be of therapeutic value in the management of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)505-511
Number of pages7
JournalInternational Journal of Oncology
Volume8
Issue number3
StatePublished - Mar 1 1996
Externally publishedYes

Fingerprint

Ascites
Vascular Endothelial Growth Factor A
Carcinoma
Growth
Neoplasms
Immune Sera
Nude Mice
Intercellular Signaling Peptides and Proteins
Serum
Mitogens
Ovarian Neoplasms
Endothelial Cells
Rabbits
Cell Line
Control Groups
Survival

Keywords

  • Angiogenesis
  • Ascites
  • Ovarian cancer
  • Tumor neovascularization
  • Vascular endothelial growth factor (VEGF)
  • Vascular permeability factor (VPF)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{5305eed6c69442959b0f6daadd029c1b,
title = "In vivo neutralization of Vascular Endothelial Growth Factor (VEGF)/Vascular Permeability Factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth",
abstract = "Vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) is emerging as an important growth factor in a variety of tumor types. As a potent endothelial cell mitogen and vascular permeabilizing agent, VEGF/VPF has the unique functional capacity to mediate the component events of solid tumor neovascularization and ascites tumor growth. In the present series of investigations, our experimental hypothesis was that VEGF/VPF is a critical mediator of ovarian carcinoma-associated ascites formation and solid tumor growth. Athymic nude mice xenotransplanted with human ovarian carcinoma cell lines received either a preimmune rabbit serum or VEGF/VPF antiserum. Compared with the control group receiving the preimmune serum, the antiserum-treated animals displayed a 10- and 12-fold reduction in ascites accumulation and solid tumor growth, respectively. The administration of a neutralizing antiserum to VEGF/VPF conferred a modest survival advantage to animals harboring intraperitoneal tumors. These data demonstrate the significance of VEGF/VPF in the pathogenesis of ovarian carcinoma and suggest that interventions targeting this growth factor and/or its receptor may be of therapeutic value in the management of ovarian cancer.",
keywords = "Angiogenesis, Ascites, Ovarian cancer, Tumor neovascularization, Vascular endothelial growth factor (VEGF), Vascular permeability factor (VPF)",
author = "Olson, {Timothy A.} and D. Mohanraj and Sundaram Ramakrishnan",
year = "1996",
month = "3",
day = "1",
language = "English (US)",
volume = "8",
pages = "505--511",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - In vivo neutralization of Vascular Endothelial Growth Factor (VEGF)/Vascular Permeability Factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth

AU - Olson, Timothy A.

AU - Mohanraj, D.

AU - Ramakrishnan, Sundaram

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) is emerging as an important growth factor in a variety of tumor types. As a potent endothelial cell mitogen and vascular permeabilizing agent, VEGF/VPF has the unique functional capacity to mediate the component events of solid tumor neovascularization and ascites tumor growth. In the present series of investigations, our experimental hypothesis was that VEGF/VPF is a critical mediator of ovarian carcinoma-associated ascites formation and solid tumor growth. Athymic nude mice xenotransplanted with human ovarian carcinoma cell lines received either a preimmune rabbit serum or VEGF/VPF antiserum. Compared with the control group receiving the preimmune serum, the antiserum-treated animals displayed a 10- and 12-fold reduction in ascites accumulation and solid tumor growth, respectively. The administration of a neutralizing antiserum to VEGF/VPF conferred a modest survival advantage to animals harboring intraperitoneal tumors. These data demonstrate the significance of VEGF/VPF in the pathogenesis of ovarian carcinoma and suggest that interventions targeting this growth factor and/or its receptor may be of therapeutic value in the management of ovarian cancer.

AB - Vascular endothelial growth factor (VEGF)/ vascular permeability factor (VPF) is emerging as an important growth factor in a variety of tumor types. As a potent endothelial cell mitogen and vascular permeabilizing agent, VEGF/VPF has the unique functional capacity to mediate the component events of solid tumor neovascularization and ascites tumor growth. In the present series of investigations, our experimental hypothesis was that VEGF/VPF is a critical mediator of ovarian carcinoma-associated ascites formation and solid tumor growth. Athymic nude mice xenotransplanted with human ovarian carcinoma cell lines received either a preimmune rabbit serum or VEGF/VPF antiserum. Compared with the control group receiving the preimmune serum, the antiserum-treated animals displayed a 10- and 12-fold reduction in ascites accumulation and solid tumor growth, respectively. The administration of a neutralizing antiserum to VEGF/VPF conferred a modest survival advantage to animals harboring intraperitoneal tumors. These data demonstrate the significance of VEGF/VPF in the pathogenesis of ovarian carcinoma and suggest that interventions targeting this growth factor and/or its receptor may be of therapeutic value in the management of ovarian cancer.

KW - Angiogenesis

KW - Ascites

KW - Ovarian cancer

KW - Tumor neovascularization

KW - Vascular endothelial growth factor (VEGF)

KW - Vascular permeability factor (VPF)

UR - http://www.scopus.com/inward/record.url?scp=0029934658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029934658&partnerID=8YFLogxK

M3 - Article

C2 - 21544389

AN - SCOPUS:0029934658

VL - 8

SP - 505

EP - 511

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -